文献速递免疫规划

24价肺炎球菌疫苗在幼儿中的安全性、耐受性与免疫原性:一项1期随机对照试验

Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial.
PubMed 文献 · Vaccine · 2024-02-14

在美国开展的一项1期盲法剂量递增主动对照多中心研究,纳入12-15月龄、已接种三剂13价肺炎球菌结合疫苗(PCV13)的幼儿,按3:2随机接受单剂Pn-MAPS24v(1 μg/2 μg/5 μg多糖)或PCV13肌内注射。结果显示各剂量组安全性可接受,局部与全身事件频率与PCV13相近,未报告疫苗相关严重不良事件;Pn-MAPS24v对全部共同血清型及多数独特血清型均诱导IgG和OPA应答。

要点

  • 12-15月龄幼儿单剂Pn-MAPS24v各剂量安全性可接受,不良事件频率与PCV13相近。
  • 未报告疫苗相关严重不良事件。
  • Pn-MAPS24v对全部共同血清型及多数独特血清型诱导IgG和OPA应答。

核心结论

  • 在12-15月龄幼儿中,单剂Pn-MAPS24v无论剂量水平均显示可接受的安全性,不良事件报告频率与PCV13受种者相似。
  • Pn-MAPS24v对全部共同血清型和大多数独特血清型均诱导IgG和OPA应答。
  • 这些结果支持在婴儿中进一步开展临床评价。

研究设计与样本

  • 1期、盲法、剂量递增、主动对照、多中心研究,在美国开展(2020年9月至2022年4月)。
  • 纳入12-15月龄、已接种三剂13价肺炎球菌结合疫苗(PCV13)的幼儿75例,随机3:2接受单剂Pn-MAPS24v(1 μg/2 μg/5 μg多糖)或PCV13肌内注射。
  • 评估接种后7天内的反应原性、180天内的治疗中出现的不良事件(TEAE)、180天内的严重不良事件(SAE)/需医疗关注的不良事件(MAAE),以及接种后30天的血清型特异性抗荚膜多糖免疫球蛋白G(IgG)和调理吞噬活性(OPA)应答。

主要发现

  • 75例入组幼儿中74例完成研究(Pn-MAPS24v 1 μg/2 μg/5 μg组分别为15/14/16例,PCV13组29例)。
  • Pn-MAPS24v 1 μg/2 μg/5 μg组局部事件频率分别为60%/67%/31%,PCV13组为55%;全身事件频率分别为67%/67%/75%,PCV13组为79%,各组范围相近。
  • TEAE报告率在Pn-MAPS24v 1 μg/2 μg/5 μg组分别为47%/40%/63%,PCV13组为52%;未报告疫苗相关SAE。
  • 接种后30天,对于13个共同血清型中的每一个,各组≥93%的受种者IgG浓度≥0.35 μg/mL;除血清型1(79%)外,>92%的受种者OPA滴度≥定量下限(LLOQ)。
  • 对于7/11个独特血清型(2/8/9N/11A/17F/22F/33F),在所有剂量水平,各组≥78%的Pn-MAPS24v受种者IgG浓度≥0.35 μg/mL,80%-100%的受种者OPA滴度≥LLOQ。

关键数值与推荐

  • 局部事件频率:Pn-MAPS24v 1 μg/2 μg/5 μg组分别为60%/67%/31%,PCV13组为55%。
  • 全身事件频率:Pn-MAPS24v 1 μg/2 μg/5 μg组分别为67%/67%/75%,PCV13组为79%。
  • TEAE报告率:Pn-MAPS24v 1 μg/2 μg/5 μg组分别为47%/40%/63%,PCV13组为52%。
  • 共同血清型IgG浓度≥0.35 μg/mL的受种者比例:各组每个共同血清型均≥93%。
  • 共同血清型OPA滴度≥LLOQ的受种者比例:除血清型1为79%外,其余>92%。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为这些结果支持在婴儿中进一步开展临床评价。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pneumococcal conjugate vaccines (PCVs) significantly reduced pneumococcal disease burden. Nevertheless, alternative approaches for controlling more serotypes are needed. Here, the safety, tolerability, and immunogenicity of a 24-valent (1/2/3/4/5/6A/6B/7F/8/9N/9V/10A/11A/12F/14/15B/17F/18C/19A/19F/20B/22F/23F/33F) pneumococcal vaccine based on Multiple Antigen-Presenting System (MAPS) technology (Pn-MAPS24v) was assessed in toddlers. METHODS: In this phase 1, blinded, dose-escalation, active-controlled multicenter study conducted in the United States (September/2020-April/2022), 12-15-month-old toddlers primed with three doses of 13-valent PCV (PCV13) were randomized 3:2 to receive a single dose of one of three Pn-MAPS24v dose levels (1 μg/2 μg/5 μg per polysaccharide) or PCV13 intramuscularly. Reactogenicity (within 7 days), treatment-emergent adverse events (TEAEs, within 180 days), serious/medically attended adverse events (SAEs/MAAEs, within 180 days), and immunogenicity (serotype-specific anti-capsular polysaccharide immunoglobulin G [IgG] and opsonophagocytic activity [OPA] responses at 30 days post-vaccination) were assessed. RESULTS: Of 75 toddlers enrolled, 74 completed the study (Pn-MAPS24v 1 μg/2 μg/5 μg: 15/14/16, PCV13: 29). Frequencies of local (60 %/67 %/31 %) and systemic events (67 %/67 %/75 %) in the Pn-MAPS24v 1 μg/2 μg/5 μg and the PCV13 (55 %, 79 %) groups were in similar ranges. TEAEs were reported by 47 %/40 %/63 % of Pn-MAPS24v 1 μg/2 μg/5 μg recipients and 52 % of PCV13 recipients. No vaccine-related SAE was reported. At 30 days post-vaccination, for each of the 13 common serotypes, ≥93 % of participants in each group had IgG concentrations ≥0.35 μg/mL; >92 % had OPA titers ≥lower limit of quantitation (LLOQ), except for serotype 1 (79 %). For 7/11 unique serotypes (2/8/9N/11A/17F/22F/33F), at all dose levels, ≥78 % of Pn-MAPS24v recipients in each group had IgG concentrations ≥0.35 μg/mL and 80 %-100 % had OPA titers ≥LLOQ. CONCLUSIONS: In 12-15-month-old toddlers, a single dose of Pn-MAPS24v showed an acceptable safety profile, regardless of dose level; AEs were reported at similar frequencies by Pn-MAPS24v and PCV13 recipients. Pn-MAPS24v elicited IgG and OPA responses to all common and most unique serotypes. These results support further clinical evaluation in infants.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Borys D, Rupp R, Smulders R, et al. Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial. Vaccine. 2024. PMID: 38360475. doi:10.1016/j.vaccine.2024.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。